Table 1 Summary of demographics and clinical characteristics of the pLGG patients included in this study (collected through the CBTN data repository)
Variable |  | Overall (n = 545) | Immunological Clusters (n = 494) | Radioimmunomic Signature (n = 150) | Clinicoradiomic Risk Stratification (n = 201) |
|---|---|---|---|---|---|
Age Range (months) |  | 0.16–253.9 | 3.06–253.9 | 4.3–253.9 | 4.3–253.9 |
Sex | Female | 250 | 220 | 67 | 97 |
| Â | Male | 295 | 274 | 83 | 104 |
Tumor Location | Basal Ganglia | 3 | 1 | - | 2 |
| Â | Brainstem | 34 | 30 | 6 | 10 |
| Â | Cerebellar | 237 | 229 | 73 | 86 |
| Â | Intraventricular | 27 | 25 | 3 | 5 |
| Â | Lobar (i.e., frontal, parietal, temporal, or occipital lobes) | 117 | 98 | 31 | 44 |
| Â | Multi-regional | 28 | 21 | 6 | 14 |
| Â | Suprasellar | 65 | 58 | 26 | 34 |
| Â | Thalamus | 16 | 14 | 5 | 6 |
| Â | Other | 18 | 18 | - | - |
WHO 2021 Classification | Diffuse astrocytoma, MYB- or MYBL1-altered | 8 | 7 | 2 | 3 |
| Â | Diffuse glioneuronal tumor with oligodendroglioma-like features and nuclear clusters | 2 | 2 | 1 | 1 |
| Â | Diffuse low-grade glioma, MAPK pathway-altered | 342 | 341 | 127 | 128 |
| Â | Ganglioglioma | 28 | 28 | 5 | 5 |
| Â | Glioneuronal and neuronal tumors | 6 | 3 | - | 3 |
| Â | Myxoid glioneuronal tumor | 3 | 3 | - | - |
| Â | Pediatric-type diffuse low-grade gliomas, NOS | 68 | 44 | 9 | 33 |
| Â | Pilocytic astrocytoma | 65 | 44 | 4 | 25 |
| Â | Pleomorphic xanthoastrocytoma | 4 | 4 | - | - |
| Â | Subependymal giant cell astrocytoma | 19 | 18 | 2 | 3 |
